Table 4.
Characteristics of patients in the clinical study
| Gender | Age (years) | Smoking status | CYP1A2 phenotype (PXT : CAF ratio) | CYP2C8 genotype | Caffeine intake | Alcohol intake | Cruciferous vegetable intake | Chargrilled meat intake | Height (m) | Weight (kg) | BMI | Current comedication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F | 53 | Nonsmoker | 0.497 | *1/*4 | High | Low | High | Low | 1.59 | 94 | 37.2 | None |
| F | 27 | Smoker | 0.492 | *1/*1 | High | Low | Low | Low | 1.65 | 65 | 23.8 | None |
| F | 40 | Nonsmoker | 0.019 | Unknown | Moderate | Low | Low | High | 1.83 | 126 | 37.6 | Lithium, naltrexone, acamprosate |
| F | 27 | Smoker | 0.451 | Unknown | Moderate | High | Low | High | 1.80 | 95 | 29.3 | Clozapine, risperidone |
| F | 57 | Nonsmoker | 0.281 | Unknown | High | High | High | Low | 1.62 | 95 | 36.2 | Lithium, valproate, oxycodone, salbutamol, fluticasone, salmeterol |
| M | 22 | Smoker | 0.034 | Unknown | Moderate | Low | Low | Low | 1.70 | 78 | 27.0 | None |
| M | 23 | Smoker | 0.194 | Unknown | Moderate | Low | Low | Low | 1.85 | 69 | 20.2 | Escitalopram |
| F | 47 | Nonsmoker | 0.493 | *1/*1 | Low | Moderate | High | Low | 1.66 | 67 | 24.3 | Gingko, vitamin C |
| M | 46 | Nonsmoker | 0.038 | *1/*1 | High | Moderate | Low | Low | 1.81 | 90 | 38.5 | Valproate, fluticasone, salbutamol, aspirin |
| M | 43 | Smoker | 0.176 | *1/*1 | Moderate | Moderate | Low | Low | 1.74 | 96 | 31.7 | Valproate, clozapine |
| F | 39 | Smoker | 2.978 | *1/*3 | High | Moderate | Low | Low | 1.72 | 78 | 26.4 | None |
| F | 22 | Nonsmoker | 0.493 | *1/*3 | Moderate | Moderate | Moderate | High | 1.68 | 68 | 24.1 | Amoxicillin, paracetamol, valproate |
| M | 27 | Nonsmoker | 0.472 | Unknown | Moderate | High | Low | High | 1.84 | 83 | 24.5 | Valproate |
| F | 34 | Smoker | 0.533 | Unknown | High | Moderate | Low | Low | 1.59 | 51 | 20.2 | None |
BMI, body mass index; CAF, caffeine; CYP, cytochrome P450; PXT, paraxanthine